Literature DB >> 8585121

Pharmacokinetics of thiocolchicoside in humans using a specific radioimmunoassay.

P Sandouk1, O Chappey, M B d'Yvoire, J M Scherrmann.   

Abstract

The myorelaxant thiocolchicoside (TC), an analogue of colchicine (COL), was assayed in plasma and urine by a radioimmunoassay (RIA) using a cross-reacting COL-specific polyclonal antibody. Cross-reactivity was 56% for TC, giving a limit of quantification of 0.5 ng/ml and a linear response from 0.5 to 100 ng/ml. Specificity was checked by cross-reactivity studies with COL analogues and by using liquid chromatography and RIA in tandem on urine samples. Two immunoreactive peaks were detected, but the nonspecific peak represented < 2% of the total urine concentration of TC. Pharmacokinetics of TC following infusion of 4 mg in two subjects revealed a moderate distribution (Vss from 31 to 35 L) and mainly extrarenal elimination (75% of the total body clearance). Terminal half-lives ranged from 2.4 to 2.7 h in plasma and from 3.2 to 3.7 h in urine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585121     DOI: 10.1097/00007691-199510000-00018

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  1 in total

1.  Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers.

Authors:  M P Ferrari; G Gatti; C Fattore; G Fedele; R Novellini
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.